RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
|Articles|January 5, 2015
The EORTC Board cordially invites you to a Plenary Session in honor of Francoise Meunier
At the Crowne Plaza Brussels - Le Palace on 12 March 2015 at 16:00
Advertisement
After 24 years of dedicated service as EORTC Director General with a major commitment to the management of pan-European cancer research, Françoise Meunier will continue her activities from 1st April 2015 as EORTC Director Special Projects.
Program
- General introduction - Roger Stupp (CH)
- Françoise Meunier’s implication in research on “Fungal infections” - Peter Donnelly (NL)
- Françoise Meunier as EORTC Director General - Alexander Eggermont (FR)
- The patients perspectives and survival issues - Isabelle Lebrocquy (NL)
- Cancer management and transatlantic cooperation - Richard Schilsky (USA)
- The EORTC Charitable Trust - Diego du Monceau de Bergendal (BE)
- EORTC future perspectives - Roger Stupp (CH)
Followed by a reception and walking dinner at Palais d’Egmont at 19:00
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financial value of RBQM, why time savings emerged as the largest driver, and what sponsors struggling to justify adoption now have that they didn't before.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simulations can identify—from overly restrictive eligibility criteria to patient dropout patterns and structural trial assumptions.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Sponsor oversight of outsourced CRO work is often robust in practice but fails inspection because oversight decisions are fragmented across systems and lack an audit trail, requiring sponsors to document oversight as a connected operating system with clear decision records, escalation pathways, and issue resolution from start to finish.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection beyond the bounded experience of a single sponsor team—and surfacing options that traditional design thinking might never have considered.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Design Flaws Trial Simulations Surface That Traditional Planning Misses
2
ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval
3
Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It
4
Quantifying the Financial Value of RBQM: Q&A with Sylviane de Viron, CluePoints, and Abigail Dirks, Tufts CSDD
5